(Q24247459)

29 July 2017

1 reference

title

Piracetam for dementia or cognitive impairment (English)

1 reference

29 July 2017

0 references

cognitive dysfunction

1 reference

Leon Flicker

1

0 references

John Grimley Evans

2

0 references

L Flicker

1

1 reference

29 July 2017

J Grimley Evans

2

1 reference

29 July 2017

G Grimley Evans

2

0 references

language of work or name

English

0 references

publication date

26 January 2004

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

2001

0 references

published in

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

CD001011

1 reference

Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Long-term and high-dose piracetam treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Clinical evaluation of compounds for the treatment of memory dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam in chronic brain failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifylline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Treatment of alcohol organic mental disorder with piracetam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

High versus low-dose piracetam in alcohol organic mental disorder: a placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Involutional dementias: new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Interaction between psychological and pharmacological treatment in cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Effect of Piracetam in Huntington’s Chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam and other structurally related nootropics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam combined with lecithin in the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Cholinergic approaches to the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam improves visuomotor and cognitive deficits in early Parkinsonism--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

On the efficacy of piracetam in geriatric patients with acute cerebral ischemia: a clinically controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam plus lecithin trials in senile dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam in alcoholic psychoses: a double-blind, crossover, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Sequelae of closed craniocerebral trauma and the efficacy of piracetam in its treatment in adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Clinical Response to Choline plus Piracetam in Senile Dementia: Relation to Red-Cell Choline Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Lecithin and piracetam in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Piracetam in Elderly Motorists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

Clinical research on comprehensive treatment of senile vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

7 January 2021

Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

7 January 2021

A Double Blind Investigation of Piracetam (Nootropil) vs Placebo in Geriatric Memory

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

7 January 2021

Efficacy and Clinical Relevance of Cognition Enhancers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

7 January 2021

Clinical efficacy of piracetam in cognitive impairment: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

7 January 2021

Cerebroprotective effect of piracetam in patients undergoing open heart surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001011

7 January 2021

10.1002/14651858.CD001011

Identifiers

DOI

1 reference

29 July 2017

1 reference